» Articles » PMID: 38673650

Current Management of In-Stent Restenosis

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Apr 27
PMID 38673650
Authors
Affiliations
Soon will be listed here.
Abstract

In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.

Citing Articles

The Design and Feasibility of Optimal Treatment for Coronary Drug-Eluting Stent In-Stent Restenosis (OPEN-ISR)-A Prospective, Randomised, Multicentre Clinical Trial.

Kulyassa P, Nemeth B, Hizoh I, Janko L, Ruzsa Z, Jambrik Z J Pers Med. 2025; 15(2).

PMID: 39997337 PMC: 11856948. DOI: 10.3390/jpm15020060.

References
1.
Faggioni M, Baber U, Sartori S, Giustino G, Cohen D, Henry T . Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017; 10(7):645-654. DOI: 10.1016/j.jcin.2016.12.003. View

2.
Aoki J, Nakazawa G, Ando K, Nakamura S, Tobaru T, Sakurada M . Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). J Cardiol. 2019; 74(5):436-442. DOI: 10.1016/j.jjcc.2019.04.011. View

3.
Rittger H, Waliszewski M, Brachmann J, Hohenforst-Schmidt W, Ohlow M, Brugger A . Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous.... JACC Cardiovasc Interv. 2015; 8(13):1695-700. DOI: 10.1016/j.jcin.2015.07.023. View

4.
Park D, Hong M, Mintz G, Lee C, Song J, Han K . Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol. 2006; 48(12):2432-9. DOI: 10.1016/j.jacc.2006.08.033. View

5.
Alfonso F, Perez-Vizcayno M, Cardenas A, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez J . A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015; 66(1):23-33. DOI: 10.1016/j.jacc.2015.04.063. View